Live Feeds
โ— LIVE Updated 40m ago ยท 8 sources tracked

Cellectis will shed 70% of workforce as part of in vivo pivot

Cellectis will shed 70% of its workforce as part of an in vivo pivot, according to corporate announcements and recent reporting. The restructuring arrives alongside financial updates showing third-quarter results for 2026. Revenue fell to $14.8 million alongside a wider nine-month loss, while earnings missed estimates by $0.42. The company outlined its ongoing business adjustments during its recent Q3 earnings call, detailing the operational shifts required to refocus its strategy toward in vivo therapeutic development.

๐ŸŽ™๏ธ

Listen to Live Briefing

Real-time synthesized voice briefing ยท Live Feeds Desk

โฑ ~2 min
Speed:
RSS Source map (8)
โšก Key Developments & Real-Time Context
Text size:
  • โœ“ Cellectis will shed 70% of its workforce as part of an in vivo pivot.
  • โœ“ Cellectis reported its third-quarter 2026 financial results and provided a business update in November 2026.
  • โœ“ Revenue fell to $14.8 million as Cellectis posted a wider nine-month loss.
  • โœ“ Cellectis ADR earnings missed by $0.42 and revenue fell short of estimates.
๐Ÿ›ก๏ธ Source Corroboration: 8 independent reporting domains (100% confidence) โฑ Read time: ~2 min

What changed

Cellectis announced plans to eliminate 70% of its personnel alongside its third-quarter financial results.

Live updates

  1. Cellectis Cuts 70% of Workforce in Strategic Pivot

    Cellectis will shed 70% of its workforce as part of an in vivo pivot, according to corporate announcements and recent reporting. The restructuring arrives alongside financial updates showing third-quarter results for 2026. Revenue fell to $14.8 million alongside a wider nine-month loss, while earnings missed estimates by $0.42. The company outlined its ongoing business adjustments during its recent Q3 earnings call, detailing the operational shifts required to refocus its strategy toward in vivo therapeutic development.

    Why it matters

    The massive staff reduction marks a major strategic shift for the genome engineering company, which is listed on Euronext Growth and Nasdaq. Biopharma firms face intense pressure to manage R&D spending amid shifting market realities and clinical priorities. Financial results released in November 2026 illustrate the revenue pressures prompting these deep operational cuts.

    What is confirmed

    • Cellectis will shed 70% of its workforce as part of an in vivo pivot.
    • Cellectis reported its third-quarter 2026 financial results and provided a business update in November 2026.
    • Revenue fell to $14.8 million as Cellectis posted a wider nine-month loss.
    • Cellectis ADR earnings missed by $0.42 and revenue fell short of estimates.

    What to watch next

    • Execution timeline and specific operational milestones for the in vivo pivot
    • Further financial disclosures regarding restructuring costs and workforce reduction expenses
    Sources used for this update (8)
    1. www.fiercebiotech.com โ€” Fierce Biotech News & Reports
    2. www.biospace.com โ€” GSK restructure will hit home, impacting 'limited' UK roles
    3. Fierce Biotech โ€” Cellectis will shed 70% of workforce as part of in vivo pivot
    4. TradingView โ€” What Cellectis (CLLS) Said on Its Q3 Earnings Call
    5. The Daily Tribune News โ€” Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update
    6. Investing.com โ€” Cellectis ADR earnings missed by $0.42, revenue fell short of estimates
    7. Stock Titan โ€” Revenue falls to $14.8M as Cellectis (CLLS) posts a wider nine-month loss.
    8. www.cellectis.com โ€” Cellectis Reports Third Quarter 2026 Financial Results and Provides a Business Update | Cellectis
    confidence 100%
๐Ÿ“Š

Community Sentiment: How do you assess this situation?

Voice your perspective ยท Real-time aggregated sentiment from the Live Feeds community